MUST Connect 2023 Singapore highlighted the cutting-edge innovations of Korean life science startups
MUST Connect 2023 Singapore, a roadshow that helps Korean life science startups expand overseas by connecting them with global pharmaceutical companies and investors, was held on Oct. 11 (Wed.) and 12 (Thu.) at Singapore Science Park. Twelve Korean startups showcased…
Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (“ANS01”), a novel small-molecule type II c-Met tyrosine kinase…
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson’s Disease (PD). Mitokinin’s lead compound, a selective PINK1 activator, is…
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the…
Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition…
Henry Schein Earns Dual Honors at Ragan’s 2023 CSR and Diversity Awards
Henry Schein, Inc. (Nasdaq: HSIC) announced today that Chairman and CEO Stanley M. Bergman was honored as Ragan’s 2023 Executive of the Year for Diversity and Inclusion. The Company also was honored by Ragan Communications, an industry leader in providing professional development, training and…
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society…
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE-671 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (T3-4N2)…
Rosies Base Appoints Paul Birkmeyer as Commercial Consultant
Rosies Base LLC, a start-up R&D company developing bio-compatible, durable, and cost-effective nano-structured alloys that are ideal for use in cutting-edge medical devices, today announced the appointment of Paul Birkmeyer, MEM, as commercial advisor. An executive and leader at innovative…
Viseon Inc. Announces Strategic Market Expansion with 4K Advanced Digital Visualization Enabling Technology
Viseon Inc. announces the company is expanding their addressable market beyond minimally invasive spine surgery to focus on several additional market segments where both open and minimally invasive surgery can benefit clinically as well as economically from the Viseon technology,…
Intellijoint Selects AcuityMD Platform to Accelerate Commercialization of Surgical Navigation Solution
AcuityMD, provider of a novel commercial platform for medical technology (MedTech) companies, announced that Intellijoint Surgical, developer of surgical planning and navigation solutions for total hip and knee joint replacements, will leverage its platform to identify new business prospects, manage pipeline, and…
VUZE Medical to Showcase Next Generation Software-based Guidance System for Spine Surgery at NASS 2023 Following FDA Filing
VUZE Medical, a privately-held company aiming to transform intra-operative guidance in minimally invasive spinal interventions, has submitted a 510(k) filing with the U.S. Food and Drug Administration (FDA) for VUZE 2.0, its second generation VUZE System. The new, investigational version of…